All In Biotech

Drug Trial Radar · NCT05438329

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,123

Planned (sponsor's estimate)

Start

Jul 19, 2022

Primary completion

Aug 13, 2027

Study completion Sep 10, 2027

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Jun 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • DB-1305/BNT325Drug

    Administered Injection of Vein (I.V.)

  • PembrolizumabCombination product

    Administered I.V.

  • BNT327Drug

    Administered I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.Time frame: up to 28 days after Cycle 1 Day 1
  2. Phase 1: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
  3. Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
  4. Maximum Tolerated Dose (MTD) of DB-1305/BNT325Time frame: At the end of Cycle 1 (each cycle is up to 21 days)
  5. Phase 1: RP2D of DB-1305/BNT325Time frame: From first study treatment administration until the initiation of Phase 2a, approximately up to 12 months.
  6. Phase 2a: Percentage of Participants with TEAEs as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
  7. Phase 2a: Percentage participants with SAEs as assessed by CTCAE v5.0.Time frame: Up to 30 days after last study treatment administration or before starting new anticancer treatment, whichever comes first.
  8. Phase 2a: Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.

Locations

93 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 139

    Bullhead City, Arizona

  • Site 103

    Cerritos, California

  • Site 136

    La Jolla, California

  • Site 127

    Los Angeles, California

  • Site 133

    Los Angeles, California

  • Site 108

    Los Angeles, California

  • Site 131

    Washington D.C., District of Columbia

  • Site 122

    Coral Springs, Florida

  • Site 142

    Hialeah, Florida

  • Site 114

    Margate, Florida

  • Site 120

    Miami, Florida

  • Site 126

    Ocala, Florida

  • Site 140

    Orange City, Florida

  • Site 109

    Plantation, Florida

  • Site 141

    St. Petersburg, Florida

  • Site 117

    Tamarac, Florida

  • Site 111

    Honolulu, Hawaii

  • Site 134

    Chicago, Illinois

  • Site 124

    Dearborn, Michigan

  • Site 106

    Detroit, Michigan

  • Site 125

    Royal Oak, Michigan

  • Site 129

    Las Vegas, Nevada

  • Site 160

    Mineola, New York

  • Site 116

    New York, New York

  • Site 102

    New York, New York

  • Site 130

    Westbury, New York

  • Site 121

    Wilson, North Carolina

  • Site 101

    Canton, Ohio

  • Site 132

    Cincinnati, Ohio

  • Site 118

    Oklahoma City, Oklahoma

  • Site 123

    Philadelphia, Pennsylvania

  • Site 112

    Pittsburgh, Pennsylvania

  • Site 105

    Nashville, Tennessee

  • Site 110

    Arlington, Texas

  • Site 104

    Houston, Texas

  • Site 115

    Houston, Texas

  • Site 119

    Tyler, Texas

  • Site 107

    Fairfax, Virginia

  • Site 135

    Falls Church, Virginia

  • Site 128

    Tacoma, Washington

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.